Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.
about
Empirical antibiotic therapy for febrile neutropenia in pediatric cancer patientsAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyNew Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological MalignanciesThe intestinal microbiota and susceptibility to infection in immunocompromised patientsProphylactic Measures During Induction for Acute Myeloid Leukemia.Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.Secular trends of blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in GreeceInfection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patientsPrognostic factors influencing infection-related mortality in patients with acute leukemia in KoreaMonotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.Pathogenesis of fulminant monkeypox with bacterial sepsis after experimental infection with West African monkeypox virus in a cynomolgus monkey.Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.The effect of an antimicrobial formulary change on hospital resistance patterns.Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment.Management of febrile neutropenia in the era of bacterial resistanceFebrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk PatientsEvaluation of febrile neutropenic episodes in adult patients with solid tumors.Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children.Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlaRapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course.Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of TurkeyBloodstream infections and mortality-related factors in febrile neutropenic cancer patients.The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients.Bloodstream infections in neutropenic cancer patients: A practical update.Antibiotic prophylaxis for patients with acute leukemia.Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center.Corynebacterium bovis line related septicemia: a case report and review of the literature.Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.Etiology and clinical course of febrile neutropenia in children with cancer.Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.The strategy of antibiotic use in critically ill neutropenic patientsUsing antimicrobial adjuvant therapy in cancer treatment: a review.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.The current spectrum of infection in cancer patients with chemotherapy related neutropenia.Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia.
P2860
Q24201480-5573D5B9-1B5C-4561-931C-03EC0B3CBCA4Q24203869-03F4B4E5-A9F0-44E4-813A-5706F49378DDQ24245774-549572BD-39D1-4772-9170-1E8872E1B101Q26799580-522FF5E2-25D1-4294-B41D-1DA3421B35B4Q26862848-A448D9C4-A772-4581-BEDD-A07F2F7BD652Q30235496-7C26602D-EE46-461B-BC4C-1EE66FB2CEBEQ30238945-07816126-8983-48D2-8E89-AB14194D7E3AQ33241976-3548E174-D229-46B0-B7F0-6027B0B7F508Q33588190-89B3D9D3-8557-45E6-8845-E626048D068AQ33599347-F39D00F1-2BED-453F-B596-DF28BC79B8ADQ33980917-82763D62-2144-4F6D-B241-5C12F9CBD26DQ34029293-E2E8FCD5-25EA-4E11-9D3C-80C50435AFB8Q34133346-4FE9BC6C-7613-4369-95EB-4036CBA92B06Q34496123-995C8BCD-AD5D-4606-8964-6D479034A4BDQ34564797-209E8044-5633-4DD0-A994-73DC08DD5FB4Q34631769-48DA1714-A223-44BD-80BE-F1E3582111EBQ34664160-C4099283-8841-43B3-A3E4-07F77B7F905BQ34673367-4EF64A38-ACAF-400D-923C-E7799BA3E414Q34676431-EA9F5F19-367D-4B2E-947A-806B1E574BA0Q34774820-6690DE09-06A8-4B54-B180-9A8C667A88E4Q35077317-FD530DA4-A2A7-4C3A-B57A-7CC0E814F10DQ35759049-60DC56FC-AE0B-444F-A8DF-8E25D76CF264Q35937307-81969F8B-412A-459D-8E1F-B365A082ED85Q36004592-9E22DF93-978C-477A-BD3B-11F801EC8B5BQ36038909-E7443050-AEA8-40FE-8161-3B5429BB9936Q36067125-CF0F0FC4-E1D1-4ECA-9252-79AE15FBBA64Q36516581-DC5D91AA-404C-46CE-A1AE-51D661507553Q36895914-B90B8EAA-E3ED-4F51-A205-BE6187F21D84Q36913345-D617CEE2-69F4-400F-AF2A-AC3A904E181AQ37071680-96872F0F-0893-4C92-B901-2F269C7C7511Q37192118-38CB6BB0-0C9E-4045-B42A-1FFC661C815BQ37201581-2EDD8670-9EB6-46CA-A8C5-43BAD1D5CFE2Q37320170-35120245-7542-4AFD-B0E9-55B7CA41E356Q37344556-09D23E84-051F-4A5F-B406-A008A007258AQ37921537-AA69B8EE-E29D-4669-A938-BCEC961722BDQ37929895-D116D5D2-EA59-4F67-B2FB-439B3E0F69AFQ38060894-104B968E-E657-451E-82D5-031C06D88DF3Q38117578-0C594CD1-12FD-4376-937F-5DDD74DE9A4DQ38131442-14F9185D-3826-4DB7-A613-F1FD05B9CB3FQ38157572-A99193E7-CB28-4481-8631-6E7C4F76ED9A
P2860
Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Changing epidemiology of infec ...... sitive and resistant bacteria.
@ast
Changing epidemiology of infec ...... sitive and resistant bacteria.
@en
type
label
Changing epidemiology of infec ...... sitive and resistant bacteria.
@ast
Changing epidemiology of infec ...... sitive and resistant bacteria.
@en
prefLabel
Changing epidemiology of infec ...... sitive and resistant bacteria.
@ast
Changing epidemiology of infec ...... sitive and resistant bacteria.
@en
P356
P1476
Changing epidemiology of infec ...... sitive and resistant bacteria.
@en
P2093
P304
P356
10.1086/598620
P407
P577
1999-09-01T00:00:00Z